FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts

Transplantation

Volumn 75, Issue 8, 2003, Pages 1110-1114

  Pan, Fan ^a   Ebbs, Aaron ^a   Wynn, Carmen ^a   Erickson, Laurie ^a   Jang, Mei Shiang ^a   Crews, Gladys ^a   Fisniku, Ogert ^a   Kobayashi, Masakazu ^a,b   Paul, Leendert C ^c   Benediktsson, Hallgrimur ^d   Jiang, Hongsi ^a,b  

^a Basic Science   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; CHRONIC GRAFT REJECTION; CONFERENCE PAPER; GRAFT SURVIVAL; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ALKYNES; ANIMALS; ANTIBODY FORMATION; GENE EXPRESSION; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; ISOXAZOLES; KIDNEY; KIDNEY TRANSPLANTATION; NITRILES; RATS; RATS, INBRED F344; RATS, INBRED LEW; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037469022     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000063704.19149.E3     Document Type: Conference Paper

References (31)

1. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923.
2. Laskowski IA, Pratschke J, Wilhelm MJ, et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13: 519.
3. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
4. Short CD, Russell S, Valentine A. Clinical audit and long-term evaluation of renal transplant recipients. Transplantation 2001; 72: S94.
5. Xu B, Sakkas LI, Slachta CA, et al. Apoptosis in chronic rejection ofhuman cardiac allografts. Transplantation 2001; 71: 1137.
6. Kreis HA, France P, Ponticelli C. Causes of late renal allograft loss: Chronic allograft dysfunction, death, and other factors. Transplantation 2001; 71: S5.
7. Savikko J, Kallio E, Taskinen E, et al. The effect of acute rejection and cyclosporin A-treatment on induction of platelet-derived growth factor and its receptors during the development of chronic rat renal allograft rejection. Transplantation 2002; 73: 506.
8. Russell M. Immunology of chronic rejection. Graft 1998; 1: 5.
9. Fellstrom B. Nonimmune risk factors for chronic renal allograft dysfunction. Transplantation 2001; 71: S10.
10. Tilney NL, Whitley WD, Diamond JR, et al. Chronic rejection: An undefined conundrum. Transplantation 1991; 52: 389.
11. Benediktsson H, Chea R, Davidoff A, et al. Antihypertensive drug treatment in chronic renal allograft rejection in the rat: Effect on structure and function. Transplantation 1996; 62: 1634.
12. Viklicky O, Zou H, Muller V, et al. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497.
13. Jin MB, Nakayama M, Ogata T, et al. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery 2002; 132: 72.
14. Xu X, Williams JW, Gong H, et al. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726: Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 1996; 52: 527.
15. Chong AS-F, Rezai K, Gebel H, et al. Effect of leflunomide and other immunosuppressive agents on T cell proliferation in vitro. Transplantation 1996; 61: 140.
16. Seimasko KF, Chong AS-F, Williams JW, et al. Regulation of B cell function by immunosuppressive agent leflunomide. Transplantation 1996; 61: 636.
17. Schorlemmer HU, Ruuth E, Kurrle R. Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine. Transpl Int 1998; 11: S340.
18. Qi Z, Ekberg H. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin. Scand J Immunol 1998; 48: 379.
19. White E, Hildemann WH, Mullen Y. Chronic kidney allograft rejections in rats. Transplantation 1969; 8: 602.
20. Fisher B, Lee S. Microvascular surgical techniques in research, with special reference to renal transplantation in the rat. Surgery 1965; 58: 904.
21. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
22. Jiang H, Wynn C, Pan F, et al. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential ability to inhibit interleukin-10 production. Transplantation 2002; 73: 1808.
23. Wasowska B, Baldwin WM, Sanfilippo F. IgG alloantibody response to donor-specific blood transfusion in differential rat strain combinations as a prediction of renal allograft survival. Transplantation 1992; 53: 175.
24. Overbergh L, Valckx D, Waer M, et al. Quantification of murine cytokine mRNAs using real time reverse transcriptase PCR. Cytokine 1999; 11: 305.
25. Paul LC. Chronic renal transplant loss (Review). Kidney Int 1995; 47: 1491.
26. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection (Review). Transplantation 1995; 59: 313.
27. Morris RE. Vascular and cellular mechanisms of chronic renal allograft rejection. Transplantation 2001; 71: S37.
28. Yilmaz S, Hayry P. The impact of acute episodes of rejection on the generation of chronic rejection in the rat renal allografts, Transplantation 1993; 56: 1153.
29. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of renal allograft rejection. Transplantation 1992; 54: 710.
30. Bilolo KK, Ouyang J, Wang X, et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allografts rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation (in press).
31. Jiang H, Sakuma S, Akiyama Y, et al. Tacrolimus versus cyclosporin A: A comparative study on rat renal allograft survival. Transpl Int 1999; 12: 92.